Vertex Pharmaceuticals Inc
NASDAQ:VRTX

Watchlist Manager
Vertex Pharmaceuticals Inc Logo
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Watchlist
Price: 494.61 USD 0.94% Market Closed
Market Cap: 127.7B USD
Have any thoughts about
Vertex Pharmaceuticals Inc?
Write Note

Wall Street
Price Targets

VRTX Price Targets Summary
Vertex Pharmaceuticals Inc

Wall Street analysts forecast VRTX stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for VRTX is 523.05 USD with a low forecast of 328.25 USD and a high forecast of 630 USD.

Lowest
Price Target
328.25 USD
34% Downside
Average
Price Target
523.05 USD
6% Upside
Highest
Price Target
630 USD
27% Upside

VRTX Last Price Targets
Vertex Pharmaceuticals Inc

The latest public price target was made on Nov 5, 2024 by Hartaj Singh from Oppenheimer , who expects VRTX stock to rise by 9% over the next 12 months. You can read more about this price target by viewing the article on StreetInsider.

Analyst Price Target Date Article
Hartaj Singh
Oppenheimer
540 USD
Upside 9%
1 week ago
Nov 5, 2024
Oppenheimer Reiterates Outperform Rating on Vertex (VRTX)
StreetInsider
Brian Abrahams
RBC Capital
451 USD
Downside 9%
1 week ago
Nov 5, 2024
Vertex (VRTX) PT Raised to $451 at RBC Capital
StreetInsider
Whitney Ijem
Canaccord Genuity
361 USD
Downside 27%
3 weeks ago
Oct 22, 2024
Canaccord Genuity Reiterates Sell Rating on Vertex (VRTX)
StreetInsider
Salveen Richter
Goldman Sachs
598 USD
Upside 21%
3 weeks ago
Oct 21, 2024
Goldman Sachs Reiterates Buy Rating on Vertex (VRTX)
StreetInsider
Evan David Seigerman
BMO Capital
566 USD
Upside 14%
3 weeks ago
Oct 21, 2024
BMO Capital Reiterates Outperform Rating on Vertex (VRTX)
StreetInsider
Geoff Meacham
Bank of America Securities
541 USD
Upside 9%
1 month ago
Oct 14, 2024
Vertex Pharmaceuticals price target lowered to $541 from $550 at BofA
TheFly
Brian Abrahams
RBC Capital
437 USD
Downside 12%
1 month ago
Oct 9, 2024
Vertex Pharmaceuticals price target raised to $437 from $425 at RBC Capital
TheFly
Hartaj Singh
Oppenheimer
550 USD
Upside 11%
3 months ago
Aug 5, 2024
Vertex (VRTX) PT Raised to $550 at Oppenheimer
StreetInsider
Joon Lee
Truist Financial
550 USD
Upside 11%
3 months ago
Aug 5, 2024
Vertex Pharmaceuticals price target raised to $550 from $508 at Truist
TheFly
Andy Chen
Wolfe Research
576 USD
Upside 16%
3 months ago
Aug 5, 2024
Vertex (VRTX) PT Raised to $576 at Wolfe Research
StreetInsider
Andrew Fein
H.C. Wainwright
600 USD
Upside 21%
3 months ago
Aug 2, 2024
Vertex Pharmaceuticals price target raised to $600 from $500 at H.C. Wainwright
TheFly
Jasper Hellweg
Argus Research
550 USD
Upside 11%
4 months ago
Jun 17, 2024
Vertex Pharmaceuticals price target raised to $550 from $465 at Argus
TheFly
Brian Abrahams
RBC Capital
421 USD
Downside 15%
5 months ago
Jun 11, 2024
Vertex (VRTX) PT Lowered to $421 at RBC Capital
StreetInsider
Evan David Seigerman
BMO Capital
500 USD
Upside 1%
5 months ago
May 31, 2024
Vertex (VRTX) PT Raised to $500 at BMO Capital
StreetInsider
Christopher Raymond
Raymond James
456 USD
Downside 8%
6 months ago
May 7, 2024
Vertex (VRTX) PT Raised to $456 at Piper Sandler
StreetInsider
Brian Abrahams
RBC Capital
424 USD
Downside 14%
6 months ago
May 7, 2024
Vertex (VRTX) PT Raised to $424 at RBC Capital
StreetInsider
Liisa Bayko
Evercore ISI
438 USD
Downside 11%
7 months ago
Apr 11, 2024
Evercore ISI Upgrades Vertex (VRTX) to Outperform
StreetInsider
Andrew Fein
H.C. Wainwright
462 USD
Downside 7%
7 months ago
Apr 11, 2024
Vertex Pharmaceuticals price target raised to $462 from $457 at H.C. Wainwright
TheFly
Unknown Analyst
Morgan Stanley
285 USD
Downside 42%
1 year ago
Feb 8, 2023
Morgan Stanley Maintains Equal-Weight on Vertex Pharmaceuticals, Lowers Price Target to $285
Benzinga
Unknown Analyst
H.C. Wainwright
326 USD
Downside 34%
1 year ago
Feb 8, 2023
HC Wainwright & Co. Maintains Buy on Vertex Pharmaceuticals, Raises Price Target to $326
Benzinga
Unknown Analyst
Leerink Partners
365 USD
Downside 26%
1 year ago
Feb 8, 2023
SVB Leerink Maintains Outperform on Vertex Pharmaceuticals, Lowers Price Target to $365
Benzinga
Show More Price Targets
Show Less Price Targets
Hartaj Singh
Oppenheimer
Price Target 540 USD
Upside/Downside 9%
View Source
Brian Abrahams
RBC Capital
Price Target 451 USD
Upside/Downside 9%
View Source
Whitney Ijem
Canaccord Genuity
Price Target 361 USD
Upside/Downside 27%
View Source
Salveen Richter
Goldman Sachs
Price Target 598 USD
Upside/Downside 21%
View Source
Evan David Seigerman
BMO Capital
Price Target 566 USD
Upside/Downside 14%
View Source
Geoff Meacham
Bank of America Securities
Price Target 541 USD
Upside/Downside 9%
View Source
Brian Abrahams
RBC Capital
Price Target 437 USD
Upside/Downside 12%
View Source
Hartaj Singh
Oppenheimer
Price Target 550 USD
Upside/Downside 11%
View Source
Joon Lee
Truist Financial
Price Target 550 USD
Upside/Downside 11%
View Source
Andy Chen
Wolfe Research
Price Target 576 USD
Upside/Downside 16%
View Source
Andrew Fein
H.C. Wainwright
Price Target 600 USD
Upside/Downside 21%
View Source
Jasper Hellweg
Argus Research
Price Target 550 USD
Upside/Downside 11%
View Source
Brian Abrahams
RBC Capital
Price Target 421 USD
Upside/Downside 15%
View Source
Evan David Seigerman
BMO Capital
Price Target 500 USD
Upside/Downside 1%
View Source
Christopher Raymond
Raymond James
Price Target 456 USD
Upside/Downside 8%
View Source
Brian Abrahams
RBC Capital
Price Target 424 USD
Upside/Downside 14%
View Source
Liisa Bayko
Evercore ISI
Price Target 438 USD
Upside/Downside 11%
View Source
Andrew Fein
H.C. Wainwright
Price Target 462 USD
Upside/Downside 7%
View Source
Unknown Analyst
Morgan Stanley
Price Target 285 USD
Upside/Downside 42%
View Source
Unknown Analyst
H.C. Wainwright
Price Target 326 USD
Upside/Downside 34%
View Source
Unknown Analyst
Leerink Partners
Price Target 365 USD
Upside/Downside 26%
View Source
Show More Price Targets
Show Less Price Targets
Vertex Pharmaceuticals Inc Competitors:
Price Targets
LVTX
LAVA Therapeutics NV
335% Upside
NBIX
Neurocrine Biosciences Inc
32% Upside
300896
Imeik Technology Development Co Ltd
27% Upside
ZYME
Zymeworks Inc
12% Downside
BIOPOR
Bioporto A/S
72% Upside
ARMP
Armata Pharmaceuticals Inc
163% Upside
688366
Shanghai Haohai Biological Technology Co Ltd
46% Upside
SWTX
SpringWorks Therapeutics Inc
99% Upside

Revenue
Forecast

Revenue Estimate
Vertex Pharmaceuticals Inc

For the last 8 years the compound annual growth rate for Vertex Pharmaceuticals Inc's revenue is 33%. The projected CAGR for the next 3 years is 10%.

33%
Past Growth
10%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Operating Income
Forecast

Operating Income Estimate
Vertex Pharmaceuticals Inc

The compound annual growth rate of Vertex Pharmaceuticals Inc's operating income for the next 3 years is 13%.

N/A
Past Growth
13%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

Net Income
Forecast

Net Income Estimate
Vertex Pharmaceuticals Inc

The compound annual growth rate of Vertex Pharmaceuticals Inc's net income for the next 3 years is 12%.

N/A
Past Growth
12%
Estimated Growth
N/A
Estimates Accuracy
N/A
Average

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is VRTX's stock price target?
Price Target
523.05 USD

According to Wall Street analysts, the average 1-year price target for VRTX is 523.05 USD with a low forecast of 328.25 USD and a high forecast of 630 USD.

What is Vertex Pharmaceuticals Inc's Revenue forecast?
Projected CAGR
10%

For the last 8 years the compound annual growth rate for Vertex Pharmaceuticals Inc's revenue is 33%. The projected CAGR for the next 3 years is 10%.

What is Vertex Pharmaceuticals Inc's Operating Income forecast?
Projected CAGR
13%

The compound annual growth rate of Vertex Pharmaceuticals Inc's operating income for the next 3 years is 13%.

What is Vertex Pharmaceuticals Inc's Net Income forecast?
Projected CAGR
12%

The compound annual growth rate of Vertex Pharmaceuticals Inc's net income for the next 3 years is 12%.

Back to Top